Samer Alsaid
@sameralsaid
Followers
357
Following
220
Media
6
Statuses
68
MD, MSc| Cardiologist & Vascular Medicine Specialist| Former Fellow @TIMIStudyGroup @BrighamWomens @harvardmed
Boston, MA
Joined January 2013
There doesn’t appear to be a floor with LDL—💥 lower is better, even in the elderly. Check out our work in @JACCJournals
1
29
126
Factor XI inhibition with abelacimab may be particularly attractive in AF patients with concomitant antiplatelet therapy. Check out our work in @CircAHA .@TIMIStudyGroup.#AFib #FactorXI #DOAC #Anticoagulation.
Abelacimab significantly reduced bleeding risk vs. rivaroxaban regardless of antiplatelet use in patients with AF @sameralsaid @wwojakowski.@rgiuglaino
0
4
8
RT @YumiKangEndo: Clinical benefit of PCK9i inhibition in people with T1DM - Manuscript can be found at
diabetesjournals.org
OBJECTIVE. To evaluate the clinical efficacy of intensive LDL cholesterol (LDL-C) lowering in type 1 diabetes mellitus (T1DM).RESEARCH DESIGN AND METHODS.
0
2
0
RT @TIMIStudyGroup: Inhibition of FXI with #abelacimab significantly reduced the relative risk of bleeding compared with riva regardless of….
0
1
0
0
0
2
RT @TIMIStudyGroup: FXI inhibition w/abelacimab consistently ↓ bleeding vs. rivaroxaban, regardless of APT use, w/↑ ARR in bleeding in thos….
0
4
0
RT @cardiomet_CE: 10) So @SidPatelMD was in the room here at #AHA24 for @cardiomet_CE as @TIMIStudyGroup #fellow Samer Al Said @sameralsaid….
0
3
0
RT @TIMIStudyGroup: Statistical Review for Clinicians: In the latest issue of their @CircAHA series, @andreabellavia and Sabina Murphy pro….
ahajournals.org
0
17
0
RT @TIMIStudyGroup: Statistical Reviews for Clinicians: in the second article of their @CircAHA series, Sabina Murphy and @andreabellavia d….
ahajournals.org
0
9
0
Extracranial systemic embolic events (SEE) in AF are less frequent than ischemic stroke but just as fatal. Our IPD analysis of 71,683 AF pts from the pivotal DOAC vs. warfarin RCTs showed that DOACs are superior to warfarin in preventing SEE #ESCCongress2024
2
4
15
RT @TIMIStudyGroup: Evolocumab appears to attenuate the excess risk of MACE in patients with obesity. @YumiKangEndo @DrM_ODonoghue @rgiugli….
0
9
0
RT @TIMIStudyGroup: #ESCCongress #LBCT Among pts undergoing invasive procedures in #AZALEA-TIMI 71, low and comparable rates of peri-proced….
0
7
0
RT @CMichaelGibson: No increase in peri-procedural bleeding when comparing long-acting factor XI inhibitor abelacimab vs. rivaroxaban. Dr.….
0
1
0
Outstanding LBCT presentation by my great friend and TIMI co-fellow @YumiKangEndo on evolocumab in patients with obesity from the FOURIER trial
0
0
6
Can biomarkers improve HF risk assessment in AF patients? Superb analysis by @PaulMHaller simultaneously published in JACC, shows hs-cTnT is as important as NTproBNP, with significant but lesser contribution from GDF-15. #COMBINE-AF
1
4
18
RT @TIMIStudyGroup: TIMI is proud to celebrate our 40th anniversary! Since 1984, we've been dedicated to advancing the knowledge and care o….
timi.org
Visit the post for more.
0
11
0
RT @marstonMD: Our CHIP analysis of 64K individuals across 5 @TIMIStudyGroup CVOTs is now published in Nature Medicine. We looked at the….
0
18
0
RT @AndreZimerman: Now in @JAMACardio:. 👴 ≥80 yrs with AFib.💊 *No* dose-reduction criteria.🎲 Lower-dose (vs. full-dose) ATC with edoxaban….
0
14
0
RT @ESC_Journals: Anticoagulation with #DOACs vs. #VKAs in patients with left #ventricular thrombus: a new meta-analysis just published in….
0
78
0
RT @TIMIStudyGroup: In this issue of @CircAHA-“Summarizing Primary Results in Clinical Trials with a Time-to-event Endpoint.” This is the f….
0
19
0